Merck (MRK) Net Cash Flow (2009 - 2026)
Merck (MRK) reported Net Cash Flow of -$9.3 billion for Q1 2026, down 95.55% year-over-year from -$208.4 billion in Q1 2025, and down 158.09% on a QoQ basis from -$3.6 billion in Q4 2025.
Merck (MRK) has 18 years of Net Cash Flow data on file, last reported at -$9.3 billion in Q1 2026.
- Quarterly Net Cash Flow fell 95.55% year-over-year to -$9.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.7 billion (down 221.63% YoY) and the FY2025 annual result came in at $809.0 million, down 87.93% from the prior year.
- Net Cash Flow declined to -$9.3 billion in Q1 2026 per MRK's latest filing, from -$3.6 billion in the prior quarter.
- Across five years, Net Cash Flow topped out at $10.2 billion in Q3 2025 and bottomed at -$9.3 billion in Q1 2026.
- The 5-year median for Net Cash Flow is -$1.0 billion (2024), against an average of -$154.9 million.
- The widest annual swing landed in 2023, when Net Cash Flow slumped 712.35%; it then jumped 245.29% in 2024.
- Tracing MRK's Net Cash Flow over 5 years: stood at $1.1 billion in 2022, then plunged by 272.52% to -$1.9 billion in 2023, then jumped by 48.46% to -$1.0 billion in 2024, then plunged by 258.23% to -$3.6 billion in 2025, then plunged by 158.09% to -$9.3 billion in 2026.
- Per Business Quant, the three latest MRK Net Cash Flow figures stand at -$9.3 billion (Q1 2026), -$3.6 billion (Q4 2025), and $10.2 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | -2.05 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 2.00 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.17 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -9.27 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 75.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 544.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -587.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.27 Bn |
| Mar 31, 2026 | -9.27 Bn |
| Dec 31, 2025 | -3.59 Bn |
| Dec 31, 2025 | -3.59 Bn |
| Sep 30, 2025 | 10.18 Bn |
| Sep 30, 2025 | 10.18 Bn |
| Jun 30, 2025 | -1.03 Bn |
| Jun 30, 2025 | -1.03 Bn |
| Mar 31, 2025 | -4.74 Bn |
| Mar 31, 2025 | -4.74 Bn |
| Dec 31, 2024 | -1.00 Bn |
| Dec 31, 2024 | -1.00 Bn |
| Sep 30, 2024 | 3.02 Bn |
| Sep 30, 2024 | 3.02 Bn |
| Jun 30, 2024 | 5.78 Bn |
| Jun 30, 2024 | 5.78 Bn |
| Mar 31, 2024 | -1.10 Bn |
| Mar 31, 2024 | -1.10 Bn |
| Dec 31, 2023 | -1.95 Bn |
| Dec 31, 2023 | -1.95 Bn |
| Sep 30, 2023 | 3.11 Bn |
| Sep 30, 2023 | 3.11 Bn |
| Jun 30, 2023 | -3.98 Bn |
| Jun 30, 2023 | -3.98 Bn |
| Mar 31, 2023 | -3.07 Bn |
| Mar 31, 2023 | -3.07 Bn |
| Dec 31, 2022 | 1.13 Bn |
| Dec 31, 2022 | 1.13 Bn |
| Sep 30, 2022 | 1.94 Bn |
| Sep 30, 2022 | 1.94 Bn |
| Jun 30, 2022 | 1.45 Bn |
| Jun 30, 2022 | 1.45 Bn |
| Mar 31, 2022 | 502.00 Mn |
| Mar 31, 2022 | 502.00 Mn |
| Dec 31, 2021 | -1.75 Bn |
| Dec 31, 2021 | -1.75 Bn |
| Sep 30, 2021 | 1.46 Bn |
| Sep 30, 2021 | 1.46 Bn |
| Jun 30, 2021 | 1.63 Bn |
| Jun 30, 2021 | 1.63 Bn |
| Mar 31, 2021 | -1.54 Bn |
| Mar 31, 2021 | -1.54 Bn |
| Dec 31, 2020 | 85.00 Mn |
| Dec 31, 2020 | 85.00 Mn |
| Sep 30, 2020 | -4.36 Bn |
| Sep 30, 2020 | -4.36 Bn |
| Jun 30, 2020 | 2.27 Bn |
| Jun 30, 2020 | 2.27 Bn |
| Mar 31, 2020 | -2.41 Bn |
| Mar 31, 2020 | -2.41 Bn |
| Dec 31, 2019 | -2.44 Bn |
| Dec 31, 2019 | -2.44 Bn |
| Sep 30, 2019 | 1.27 Bn |
| Sep 30, 2019 | 1.27 Bn |
| Jun 30, 2019 | -1.43 Bn |
| Jun 30, 2019 | -1.43 Bn |
| Mar 31, 2019 | 90.00 Mn |
| Mar 31, 2019 | 90.00 Mn |
| Dec 31, 2018 | 204.00 Mn |
| Dec 31, 2018 | 204.00 Mn |
| Sep 30, 2018 | 2.55 Bn |
| Sep 30, 2018 | 2.55 Bn |
| Jun 30, 2018 | 1.09 Bn |
| Jun 30, 2018 | 1.09 Bn |
| Mar 31, 2018 | -1.76 Bn |
| Mar 31, 2018 | -1.76 Bn |
| Dec 31, 2017 | -1.82 Bn |
| Dec 31, 2017 | -1.82 Bn |
| Sep 30, 2017 | 36.00 Mn |
| Sep 30, 2017 | 36.00 Mn |
| Jun 30, 2017 | -4.03 Bn |
| Jun 30, 2017 | -4.03 Bn |
| Mar 31, 2017 | 4.94 Bn |
| Mar 31, 2017 | 4.94 Bn |
| Dec 31, 2016 | -908.00 Mn |
| Dec 31, 2016 | -908.00 Mn |
| Sep 30, 2016 | 1.25 Bn |
| Sep 30, 2016 | 1.25 Bn |
| Jun 30, 2016 | -3.26 Bn |
| Jun 30, 2016 | -3.26 Bn |
| Mar 31, 2016 | 1.05 Bn |
| Mar 31, 2016 | 1.05 Bn |
| Dec 31, 2015 | 1.22 Bn |
| Dec 31, 2015 | 1.22 Bn |
| Sep 30, 2015 | 711.00 Mn |
| Sep 30, 2015 | 711.00 Mn |
| Jun 30, 2015 | -375.00 Mn |
| Jun 30, 2015 | -375.00 Mn |
| Mar 31, 2015 | 834.00 Mn |
| Mar 31, 2015 | 834.00 Mn |
| Dec 31, 2014 | -3.60 Bn |
| Dec 31, 2014 | -3.60 Bn |
| Sep 30, 2014 | 1.91 Bn |
| Sep 30, 2014 | 1.91 Bn |
| Jun 30, 2014 | -6.10 Bn |
| Jun 30, 2014 | -6.10 Bn |
| Mar 31, 2014 | 174.00 Mn |
| Mar 31, 2014 | 174.00 Mn |
| Dec 31, 2013 | 1.58 Bn |
| Dec 31, 2013 | 1.58 Bn |
| Sep 30, 2013 | -1.00 Bn |
| Sep 30, 2013 | -1.00 Bn |
| Jun 30, 2013 | 2.17 Bn |
| Jun 30, 2013 | 2.17 Bn |
| Mar 31, 2013 | -233.00 Mn |
| Mar 31, 2013 | -233.00 Mn |
| Dec 31, 2012 | -3.81 Bn |
| Dec 31, 2012 | -3.81 Bn |
| Sep 30, 2012 | 562.00 Mn |
| Sep 30, 2012 | 562.00 Mn |
| Jun 30, 2012 | 2.04 Bn |
| Jun 30, 2012 | 2.04 Bn |
| Mar 31, 2012 | 1.16 Bn |
| Mar 31, 2012 | 1.16 Bn |
| Dec 31, 2011 | -682.00 Mn |
| Dec 31, 2011 | -682.00 Mn |
| Sep 30, 2011 | 2.07 Bn |
| Sep 30, 2011 | 2.07 Bn |
| Jun 30, 2011 | 547.00 Mn |
| Jun 30, 2011 | 547.00 Mn |
| Mar 31, 2011 | 654.00 Mn |
| Mar 31, 2011 | 654.00 Mn |
| Dec 31, 2010 | 1.24 Bn |
| Dec 31, 2010 | 1.24 Bn |
| Sep 30, 2010 | 1.16 Bn |
| Sep 30, 2010 | 1.16 Bn |
| Jun 30, 2010 | 326.00 Mn |
| Jun 30, 2010 | 326.00 Mn |
| Mar 31, 2010 | -840.00 Mn |
| Mar 31, 2010 | -840.00 Mn |
| Dec 31, 2009 | -12.47 Bn |
| Dec 31, 2009 | -12.47 Bn |
| Sep 30, 2009 | 9.33 Bn |
| Sep 30, 2009 | 9.33 Bn |
| Jun 30, 2009 | 6.34 Bn |
| Jun 30, 2009 | 6.34 Bn |
| Mar 31, 2009 | 1.71 Bn |
| Mar 31, 2009 | 1.71 Bn |